PYXIS ONCOL.INC. DL-,0001 Aktie

Wells Fargo raises the price target for Pyxis Oncology to $19 and sees peak sales potential for the new drug MICVO of about $2 billion. Pyxis focuses on antibody‑drug conjugates (ADCs) for targeted oncology. Phase‑1 data show a disease control rate of 94% in head‑and‑neck tumors and support the pipeline valuation. » Mere på finanzen.net

Pyxis Oncology shares fell 7% after the release of updated phase-1 monotherapy data for Micvotabart Pelidotin (MICVO). Among 33 evaluable patients, the confirmed objective response rate was 36% and the disease control rate 94%; median progression-free survival was 6.2 months and the 12‑month overall survival probability was 79%; median overall survival has not yet been reached. The safety profile showed no new signals: 54.3% of patients experienced treatment-related adverse events grade ≥3, 14.3% discontinued treatment, and there were no treatment-related deaths. Pyxis plans a registrational, randomized phase‑3 trial called Headliner with about 500 patients in mid-2027 after an expected end-of-phase-2 meeting with the FDA. » Mere på de.investing.com

Pyxis Oncology presented updated clinical data in a webcast from the phase-1 monotherapy study of Micvotabart Pelidotin in patients with recurrent/metastatic squamous cell carcinoma of the head and neck, including detailed analyses of patients who received 5.4 mg/kg every three weeks. Updated efficacy and safety data from the expansion study were also shown. The agent, an antibody–drug conjugate targeting extradomain‑B of fibronectin, has FDA Fast Track status and is also being investigated in combination with pembrolizumab. » Mere på de.investing.com